| Nov 22 |
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
|
| Nov 18 |
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
|
| Nov 15 |
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
|
| Nov 12 |
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
|
| Nov 11 |
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
|
| Nov 11 |
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
|
| Nov 7 |
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
|
| Nov 5 |
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)
|
| Nov 4 |
/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
|
| Nov 4 |
IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04
|
